Results 211 to 220 of about 350,788 (241)

Adjuvant chemotherapy is not for everyone [PDF]

Breast Cancer Research and Treatment, 2010
The history of breast cancer therapy is cyclical [1]. Each new treatment, whether surgery, hormone therapy, or chemotherapy is initially applied to all patients, but with time, usually 10–20 years, it becomes clear that the overall benefit is substantially smaller than first anticipated because only a portion of treated patients derive any benefit ...
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Perspectives in adjuvant chemotherapy in NSCLC

Expert Review of Respiratory Medicine, 2007
In 2007 the long-term outcome of lung cancer is still disappointing, with a 5-year survival rate not exceeding 15%. However, small but significant improvements in survival times have been achieved in the last decade. This progress has been achieved through the improvement of surgical techniques and following the introduction of more effective ...
Selvaggi, Giovanni, Scagliotti, Giorgio Vittorio   +1 more
openaire   +4 more sources

Adjuvant Intravesical Chemotherapy

2021
In 2018, there were an estimated 81,000 new cases of bladder cancer in the USA with over 17,000 cancer-related deaths.(Siegel et al., CA Cancer J Clin. 68:7–30, 2018) About 75% of these newly diagnosed cases are nonmuscle-invasive bladder cancer (NMIBC).
Christopher R. Haas, James M. McKiernan, Joseph M. Caputo   +2 more
openaire   +2 more sources

Adjuvant Chemotherapy for Soft Tissue Sarcomas

Hematology/Oncology Clinics of North America, 1986
Despite considerable interest in this subject and the completion of a number of randomized trials, the use of adjuvant chemotherapy after definitive local treatment for patients with soft tissue sarcomas remains problematic. This article reviews randomized clinical trials completed and published to date, and explores new strategies for future studies.
Vivien H.C. Bramwell, Vivien H.C. Bramwell, Wilson C. Mertens   +2 more
openaire   +8 more sources

Surgery and adjuvant chemotherapy

International Journal of Clinical Oncology, 2008
It was clearly demonstrated that good local control by either radiotherapy or D2 surgery is essential to cure gastric cancer. D2 surgery can be carried out safely with a large volume of patients and can provide better survival than limited surgery. More extended surgery than D2 cannot provide better survival and causes greater morbidity; therefore, it ...
openaire   +3 more sources

Rationale for adjuvant chemotherapy

Cancer, 1977
Surgery or radiation therapy fails to cure clinically evident human cancer, in the main, if the disease is systemic (has metastasized) when first recognized, because neither modality can effectively remove or kill distant and/or unrecognized metastases.
openaire   +3 more sources

Adjuvant castration versus adjuvant chemotherapy

International Journal of Radiation Oncology*Biology*Physics, 1978
Furthermore, in premenopausal women under 45 years of age Meakin et al.” failed to observe a significant difference in terms of delay of recurrence and prolongation of survival between those who had radical mastectomy (RM) and RM plus ovarian irradiation (RT). Since histologically positive axillary lymph nodes were identified in 87% (RM) and in 98% (RT)
openaire   +3 more sources

Adjuvant Chemotherapy

Archives of Surgery, 1977
The remarks of Drs Jamieson and Ludbrook revive recent controversy in major scientific journals and in the public press. However, adjuvant chemotherapy has been widely accepted by the public and the profession; there is a case for presenting the alternative view.
openaire   +2 more sources

Adjuvant chemotherapy for colon cancer

Best Practice & Research Clinical Gastroenterology, 2002
Colorectal cancer is one of the most frequent cancers in the world, especially in occidental countries. The primary curative therapy is surgical resection of the tumour. Within the last 15 years, appropriately powered prospective randomized trials have demonstrated that adjuvant post-operative chemotherapy should be the standard treatment for stage III
Valérie Boige, Michel Ducreux
openaire   +3 more sources

Adjuvant chemotherapy in pancreatic cancer

International journal of pancreatology, 1997
There is increasing interest in the use of adjuvant treatment for pancreatic cancer since although postoperative mortality is much improved, median long-term survival is only on the order of 11-15 mo. Despite a proliferation of studies in advanced pancreatic cancer indicating a benefit for chemotherapy, there has only been one small randomized adjuvant
Simon R. Bramhall, John P. Neoptolemos
openaire   +3 more sources